Navigation Links
Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:4/24/2008

CRANBURY, N.J., April 24 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008, at 2:20 p.m. EDT, at the Ritz-Carlton in Key Biscayne, Florida.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website for 30 days until May 30, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

CONTACTS:

Investors: Media:

John Quirk Cory Tromblee

Porter Novelli Life Sciences Porter Novelli Life Sciences

(212) 601-8296 (617) 897-8294


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... RUTHERFORD, N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... ended June 30, 2014. Highlights ... $61.6 million in the same period last year. , ... $11.4 million in the same period last year (see table ... 2014 sales guidance increased, excluding the impact of foreign currency, ...
(Date:7/31/2014)... 01, 2014 “2014 Deep ... Resin Industry” is a professional and in-depth ... report introduces Polyurethane Resin basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/31/2014)... the British mathematician (1912-1954), is famous for a number ... century. In 1936 he published a paper, which laid ... concept of a computer algorithm. He next played a ... machines which cracked the German military codes, enabling the ... And in the late 1940,s he turned his attention ...
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... review activities, TSX Exchange Symbol: RVX, ... Resverlogix,Corp. ("Resverlogix" or the "Company") (TSX:RVX) the Board ... discussions with third parties,feel it is prudent to ... announced strategic review process of January 25, 2007. ...
... Exchange Symbol: MS, EDMONTON, Sept. 3 /PRNewswire-FirstCall/ ... in the treatment of multiple sclerosis (MS), announced,today ... bid. Under the bid,which will be conducted pursuant ... the Company may purchase up to 1,000,000 of ...
... China, Sept. 3 ,Acesys Pharmatech and Provid Pharmaceuticals ... expertise and project management,capabilities of Provid in the ... structure of Acesys in China., The combined ... of medicinal chemistry for clients in the pharmaceutical ...
Cached Biology Technology:Resverlogix Board of Directors Update 2BioMS Medical announces its intention to renew a normal course issuer bid 2BioMS Medical announces its intention to renew a normal course issuer bid 3Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2
(Date:8/1/2014)... of the most diverse families in the ocean today ... -- originated more than 400 million years ago in ... those of its modern members. This Geology ... published online on 25 July 2014, tracks the remarkable ... , At is origin, the Lucinidae family remained at ...
(Date:8/1/2014)... a more effective way to control the condition, thanks ... National University of Singapore (NUS). , The team, led ... Pharmacology at the NUS Yong Loo Lin School of ... PhD graduate from the Saw Swee Hock School of ... herbal-based anti-malarial drug, can be used to control asthma, ...
(Date:8/1/2014)... two Simon Fraser University research associates, cite new ... collaborate closely on minimizing damage to the natural ... Maureen Ryan, David H. Smith Conservation Research Fellows ... international co-authors of the newly published research in ... , Shale gas development is the extraction of ...
Breaking Biology News(10 mins):Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14NUS study shows effectiveness of common anti-malarial drug in controlling asthma 2Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3
... the skeletal support for the membrane in animal cells ... the Physico Chemistry Curie Unit at the Curie Institute ... layer beneath the cell outer membrane forms beyond a ... within the cellular system. These findings, which offer a ...
... In India most people who are HIV positive don,t ... available. It would therefore meet international standards of cost-effectiveness ... every person in the billion-plus population every five years according ... One . The findings are based on a careful ...
... 2013 at the Best Western Ramkota Rapid City Hotel & ... Society of America,s North Central Branch holds its 68th Annual ... Forests pests, such as the mountain pine beetle and the ... the western corn rootworm, the soybean aphid, and the twospotted ...
Cached Biology News:Cost-effective: Universal HIV testing in India 2Cost-effective: Universal HIV testing in India 3Cost-effective: Universal HIV testing in India 4
...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
... for cell culture scale-up, these culture chambers ... - 10 9 range and are ... spinner flasks. • High mechanical • strength ... prior to shipping • Certified nonpyrogenic and ...
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)...
Biology Products: